SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
NEW YORK, March 21, 2016 -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Migralex™, a commercially available over-the-counter medication for treating pain.
As part of the transaction, all assets from Migralex, Inc. will be transferred to Ember Therapeutics, Inc.
“This is our second acquisition this quarter. The addition of a great brand, such as Migralex™, to our pipeline will allow us to provide relief to over 150 million Americans suffering from recurrent pain,” said Joseph Hernandez, Executive Chairman of Ember Therapeutics, Inc. “Furthermore, as Migralex™ is a commercial stage asset, the revenue generated by this product will help further the development of our two Phase 3 ready clinical programs in osteoarthritis and regenerative medicine.”
As a result of over 25 years of research, world renowned neurologist, leading pain expert and founder of the New York Headache Center, Dr. Alexander Mauskop has developed and patented a breakthrough headache medicine that has been clinically proven to be highly effective in relieving most types of pain, including arthritis pain, tension headaches, sinus headaches, stress headaches, menstrual headaches, and various other pains. Dr. Mauskop’s Migralex™ is a patented product and is the strongest combination pain medicine available without a prescription. Its special rapid release formula gives fast acting relief, and is gentle on the stomach. Migralex™ reduces side effects common with other OTC pain relievers. It contains no caffeine, sodium or preservatives, and contains magnesium as a buffering agent.
Migralex™ is currently available at CVS, local pharmacies, and online at Amazon.com and the product website www.migralex.com. To learn more about Migralex™ please access www.migralex.com.
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a pharmaceutical company developing targeted therapies for pain, osteoarthritis, kidney fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has a commercial stage pain product and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com.
The Ruth Group Lee Roth (investors) (646) 536-7012 [email protected]
